AstraZeneca has agreed to purchase Belgium-based EsoBiotec for up to $1 billion. The acquisition is aimed at enhancing ...

AstraZeneca’s EsoBiotec acquisition is the latest in a series of deals struck by the pharma giant to secure a place in the next wave of cell therapies for cancer and immune-mediated diseases.

Explore the unexpected factors that may influence brain tumor risk and learn practical steps to protect your health and well-being.

Skin tags may be painless and generally harmless, but you should get them checked out. They could be a symptom of something ...

- Biopharmaceutical company recognized for innovation in the development of immune-modulatory therapeutic cancer vaccines - ...

Glioblastoma (GBM), one of the most aggressive types of brain cancer, is one of the greatest challenges for medicine, both ...

The transaction is expected to close in the second quarter of 2025, which will include AstraZeneca will buying all ...

The FDA has granted orphan drug designation to PEP-010 for pancreatic cancer, advancing its development as a potential novel ...

AstraZeneca, headquartered in Cambridge, could pay up to $1 billion on a cash and debt-free basis for Belgian company ...

For the first time, researchers outline new therapeutic avenues for a rare patient group with unmet clinical needs, paving ...

AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell ...

Taiho Pharmaceutical Co., Ltd. (hereinafter "Taiho Pharmaceutical") and Araris Biotech AG (hereinafter "Araris"), a Swiss biotechnology company developing next-generation antibody drug conjugates ...